Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

any will continue advancing its highest priority programs (see "Research and Development Expenses") while operating within an annual burn rate of approximately $9 million to $10 million (reduced from previously expected range of $11 million to $13 million principally due to delaying some non-essential development activities). The magnitude of spending in the Company's development programs will be dependent on the licensing status of the celgosivir program and results in the various programs. We may need to increase or decrease our annual burn rate in response to such results. MIGENIX is likely to need to raise additional funds in support of its operations and there is no assurance that such funds can be obtained.

Outstanding Shares

There are currently 94,463,806 (January 31, 2008: 94,463,806; April 30, 2007: 94,237,205) common shares outstanding; 29,465 convertible royalty participation units (January 31, 2008 and April 30, 2007: 29,465); and 5,250,000 (January 31, 2008: 5,250,000; April 30, 2007: 9,350,000) preferred shares outstanding. During Q3/08 we redeemed 4,000,000 Series E preferred shares for the aggregate sum of US$1 as the milestone obligations associated with these shares expired August 31, 2007.

----------------------------------------------------------------------- --

Conference Call

Investors, analysts and the media are invited to participate in a conference call and webcast on Thursday, March 13 at 11:00 a.m. ET (8:00 a.m. PT) to discuss this announcement. An update on company activities will also be provided. To participate in the conference call, please dial 416-644-3417 or 1-800-732-0232. The call will be available for replay until March 27, 2008 by calling 416-640-1917 or 1-877-289-8525 and entering the pass code 21263848 followed by the number sign. The live and archived webcast will be accessible through the company's website at http://www.migenix.com for the
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Washington, USA (PRWEB) September 30, 2014 ... yet efficient arrangements that have evolved in nature over ... biomimetic and bioinspired materials for applications in biophotonics ... Biomedical Optics . The journal is published by SPIE, ... SPIE Digital Library. Several of the peer-reviewed articles are ...
(Date:10/1/2014)... 2014 Slone Partners , a ... IT, and Laboratory Testing industries, reported a 120% increase ... director level and above from July 2013 to July ... top of rapid breakthroughs in diagnostics, reimbursement has failed ... have been forced to fold, consolidate, or carry on ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 The U.S. ... to Southern Illinois University Edwardsville as part of the ... initiative. The funding is co-administered by the Department of ... Biden, Secretary of Labor Thomas E. Perez and Secretary ... million in job-driven training grants to nearly 270 colleges ...
(Date:10/1/2014)... Industry leaders from retail ... around the theme, ,Commercial Opportunities in the Era of ... Elsevier , a world-leading provider of scientific, ... a gathering of some of the industry,s most prominent ... today and in the future. The Elsevier ...
Breaking Biology Technology:Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... Oct. 9 BioElectronics,Corporation, (Pink Sheets: BIEL), ... has cleared ActiPatch for sale by its,distributor, ... that the experienced sales professionals of,Endotherapeutics will ... team has many decades of experience in ...
... Oct. 8 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) ... 11,2007, at 1:00 p.m. Pacific Daylight Time. Mike Grey, ... an overview of the,Company,s oncology pipeline. The conference is ... Hotel in San Francisco. A live webcast of ...
... Inverness Medical,Innovations (Amex: IMA ) today announced ... Panbio Ltd, an Australian company traded on,the Australian Securities ... all of the issued shares in Panbio for AUD ... issued share capital of,Panbio at approximately AUD 41 million, ...
Cached Biology Technology:Australian Therapeutics Goods Administration Approval for ActiPatch Achieved 2Inverness Medical Innovations Agrees to Acquire Panbio Ltd. 2
(Date:9/30/2014)... comes to using marijuana, new research, involving mice and ... Journal of Leukocyte Biology , suggests that ... you should. That,s because a team of Italian scientists ... serious long-term damage to the immune system. This damage ... such as multiple sclerosis, inflammatory bowel disease and rheumatoid ...
(Date:9/30/2014)... release is available in German . ... their behavioural response to risky situations such as exposure ... Ornithology now found in a long-term study on different ... both metabolic rate and ambient temperature. High metabolic rates ... as in these scenarios birds were more likely to ...
(Date:9/30/2014)... -- Winners of The Economist,s prestigious Innovation awards 2014 ... place at the JW Marriott Hong Kong on Friday, October 10 ... their experiences and the lessons those hold for others. The awards, ... the past decade, will be presented at a ceremony in ... will be the first time the ceremony has come to ...
Breaking Biology News(10 mins):Adolescent exposure to thc may cause immune systems to go up in smoke 2Risky metabolism 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... the first time, scientists at Weill Cornell Medical College in ... mechanism that,s crucial to how brain cells communicate. In ... as to how key cellular processes -- called endocytosis and ... in this week,s online edition of Proceedings of the National ...
... appear to have been influenced by RNA polymerase II. ... DNA into messenger-RNA (mRNA), which in turn is the ... is highly conserved through evolution, with many of its ... Single-cell organisms were already in existence 500 million ...
... whose mothers, sisters or daughters test positive for a cancer-causing ... disease but are unaware of that risk. That is ... exploring how families communicate genetic test results. Like their female ... in the BRCA 1 or 2 genes. Male carriers ...
Cached Biology News:Breakthrough technology observes synapse in real time, supporting theory of vesicular recycling 2Breakthrough technology observes synapse in real time, supporting theory of vesicular recycling 3Evolution with a restricted number of genes 2Men unaware of their cancer risk when female relatives test positive for BRCA mutation 2
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
... Cyclin D2 is a G1 cyclin ... strong candidate for a proto-oncogene. cyclin ... cdk4 and/or cdk6. Species Reactivity: Human, ... NeoMarkers DCS-3.1 MAb is particularly well suited ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: